NYSE:ABBV Stock Report
Market Cap $380.62B
$215.43
+1.17%
+$2.50 today
Market Cap
$380.62B
P/E Ratio
Discount21.14
Sector: 25.38
EPS
$2.65
Volume
5.2M
Year High
$244.81
Year Low
$181.73
50-Day MA
Above$208.36
200-Day MA
Below$219.64
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. currently trades with a positive momentum supported by a broadly bullish analyst consensus rating of 'Buy' and a consensus price target of approximately $257.54, representing an upside of about 18% from the current price near $217.58. The stock has shown resilience with no recent rating downgrades, reflecting confidence in AbbVie's diversified portfolio and steady earnings growth. The company’s Q1 2026 earnings report beat expectations, driven by a 7.7% year-over-year increase in adjusted EPS to $2.65 and strong performance in key segments such as Botox Cosmetic, which saw a 25.8% sales increase in the U.S. market. Recent regulatory milestones have bolstered AbbVie's growth outlook, including FDA approval of Decnupaz (pivekimab sunirine) for the rare blood cancer BPDCN, marking a strategic expansion into ultra-rare oncology indications. Additionally, the European Commission authorized an expanded label for VENCLYXTO in combination therapies for previously untreated chronic lymphocytic leukemia, enhancing AbbVie's oncology franchise in Europe. These approvals validate AbbVie's strategic acquisitions, such as ImmunoGen, and pipeline investments, positioning the company well for future revenue growth. AbbVie's growth drivers are further supported by ongoing clinical progress in neuroscience and psychiatry, with promising Phase 3 and Phase 2 trial data for treatments targeting Parkinson's disease and schizophrenia. The company’s strong cash flow exceeding $20 billion annually underpins sustained R&D investment and shareholder returns. However, AbbVie faces challenges including biosimilar competition impacting legacy products like Humira, safety concerns with some immunology drugs, and regulatory and macroeconomic risks that could affect execution and market dynamics. Looking forward, AbbVie’s balanced portfolio across immunology, oncology, aesthetics, and neuroscience, combined with strategic acquisitions and regulatory progress, provides a solid foundation for growth. Investors should monitor upcoming clinical trial readouts, regulatory decisions, and competitive landscape developments to assess the sustainability of AbbVie's momentum and valuation.
Price Target
41 analysts$257.54
Range: $223.00
→
$298.00
Upside Potential
+19.6%
From current price
Consensus Rating
Rating Distribution
Buy
Hold
Sell
AbbVie benefits from a strong and diversified product portfolio with multiple growth engines. The company’s Q1 2026 earnings beat consensus estimates, driven by a 7.7% increase in adjusted EPS and robust sales growth in Botox Cosmetic and the aesthetics segment, particularly in the U.S. market. Regulatory progress has been a key catalyst, highlighted by the FDA approval of Decnupaz for the rare blood cancer BPDCN, which expands AbbVie's presence in ultra-rare oncology indications and validates its strategic acquisition of ImmunoGen. Additionally, the European Commission’s expanded label for VENCLYXTO in combination therapies for chronic lymphocytic leukemia significantly broadens AbbVie's oncology footprint in Europe, potentially driving incremental revenue. Pipeline advancements further support AbbVie's growth outlook, with positive Phase 3 data for Parkinson's disease treatment Tavapadon and Phase 2 data for Emraclidine in schizophrenia, alongside the anticipated expansion of infectious disease treatments such as MAVIRET in the EU. Strategic acquisitions like Aliada Therapeutics and Gilgamesh Pharmaceuticals enhance AbbVie's neuroscience and psychiatry pipelines, positioning the company to capitalize on growing demand for innovative therapies. The company’s strong cash flow generation exceeding $20 billion annually enables sustained R&D investment and shareholder returns, reinforcing its competitive advantages in a favorable regulatory and industry environment.
AbbVie faces several notable risks that could impact its growth trajectory. The company is exposed to competitive pressures from biosimilars, particularly affecting revenue from its former flagship drug Humira. Safety concerns related to immunology drugs such as Rinvoq and Skyrizi, including cardiovascular and infection risks, may lead to increased regulatory scrutiny and affect market acceptance. Oncology drugs like ibrutinib and venetoclax also require careful management of adverse events to maintain their market position. Execution risks remain in advancing the pipeline and integrating recent acquisitions effectively. Industry-wide challenges include evolving regulatory landscapes that may increase compliance costs and delay approvals, pricing pressures from payers, and market saturation in certain therapeutic areas. Macro risks such as global economic uncertainties, trade disputes, currency fluctuations, and climate-related operational risks add further complexity. Valuation concerns arise from elevated expectations reflected in analyst price targets and the stock’s forward P/E ratio, which could limit upside if growth disappoints. Ongoing litigation risks and the need for strong clinical and commercial execution remain critical to sustaining investor confidence.
Explore similar companies in the Healthcare sector